AUS
NZ
UK
CA
USA
IND
Apptly Health Technologies Corp. (CSE: APPT) has revealed a strategic alliance incorporating Bryleos, a woman-owned life sciences firm specializing in NAD+ research and cellular health formulations, into its UberDoc direct-pay healthcare marketplace. This collaboration further broadens Apptly's platform ecosystem by extending UberDoc's transparent-access model beyond specialist care. Bryleos contributes peer-reviewed research and patent-pending technology, enabling UberDoc to expand its service offerings and diversify revenue streams.
Key Highlights
- Apptly Health Technologies Corp. (CSE: APPT) partners with Bryleos (BioNADrx Holdings, Inc.), a woman-owned life sciences enterprise.
- Bryleos is now integrated into the UberDoc marketplace with a dedicated presence for patients and healthcare providers.
- Bryleos operates a patent-pending LathMized ae NAD+ platform targeting metabolic changes linked to aging and cellular resilience.
- The partnership is founded on randomized, placebo-controlled human studies with results published in peer-reviewed journals.
- UberDoc features over 5,000 specialist physicians and clinicians across more than 55 specialties nationwide.
- Apptly discloses its commercial relationship with Bryleos in line with relevant advertising and endorsement regulations.
Bryleos Integrated into UberDoc with Dedicated Marketplace Platform
Apptly Health Technologies Corp. has formalized its collaboration with Bryleos by integrating the company into the UberDoc direct-pay healthcare marketplace. This onboarding offers patients and physicians direct access to Bryleos’ products through a unified, transparent platform. This marks a strategic expansion of UberDoc’s ecosystem, which traditionally connects patients with board-certified specialists across multiple medical fields.
The partnership features Bryleos prominently within UberDoc’s platform and communications channels. Apptly emphasizes full disclosure of this commercial relationship in compliance with advertising and endorsement standards, underscoring transparency as a foundational principle. This disclosure ensures that investors and users are fully informed about the nature of the partnership.
Scientific Foundation in NAD+ and Cellular Health Research
Bryleos is a woman-owned life sciences company specializing in NAD+ science and oral formulations supporting cellular health. Its core technology, the LathMized ae NAD+ platform, targets metabolic processes associated with aging, recovery, and cellular resilience. This positions Bryleos within the expanding precision nutrition and metabolic health sector, increasingly recognized by healthcare consumers and professionals.
The partnership is supported by randomized, placebo-controlled human research with findings published in peer-reviewed literature, distinguishing it from many wellness products. Bryleos also holds patent-pending status for its NAD+ formulation platform, protecting its intellectual property.
Strategic Platform Expansion and Revenue Diversification
The Bryleos collaboration aligns with Apptly’s broader strategy to extend UberDoc beyond specialist medical care by building diverse revenue streams. Originally designed as a direct-pay marketplace connecting patients with board-certified specialists at transparent prices without referrals or insurance, UberDoc now incorporates complementary health and wellness products.
By integrating companies focused on preventive health, cellular wellness, and metabolic support, Apptly aims to position UberDoc as a comprehensive health-access platform. This diversification appeals to patients seeking integrated solutions and offers shareholders new commercial opportunities beyond traditional specialist consultations.
UberDoc’s Extensive Marketplace Reach
UberDoc operates as a physician-founded, surgeon-led marketplace with significant scale, featuring over 5,000 specialist physicians and clinicians across 55+ specialties in all 50 states. This extensive network provides Bryleos immediate access to an engaged user base of healthcare professionals and patients within the UberDoc ecosystem.
The platform’s wide specialist coverage across the U.S. indicates strong market penetration in the direct-pay healthcare sector. Adding Bryleos leverages existing patient-physician relationships and platform capabilities, facilitating rapid market reach without the need for separate infrastructure.
Leadership Emphasizes Transparent, Credible Healthcare Innovation
Dr. Paula M. Muto, Founder and Interim CEO of Apptly and practicing vascular surgeon, described the partnership as embodying UberDoc’s commitment to direct, transparent access to healthcare innovations. She highlighted the focus on building a trusted platform where patients and physicians can explore credible health options in one place.
Board Member John Dvor expressed pride in partnering with Bryleos, a woman-owned company committed to published, peer-reviewed human research. He emphasized that scientific rigor and quality standards are key criteria for companies featured on UberDoc, reinforcing its evidence-based health solution positioning.
Maintaining Clinical Autonomy and Patient-Physician Decision Making
The announcement clarifies that Apptly does not provide medical advice; all clinical and treatment decisions remain between patients and their physicians. This distinction defines UberDoc’s role as a connection and information platform rather than a medical guidance provider.
This framework limits liability for Apptly and partners regarding medical outcomes, positioning UberDoc as a transparent intermediary. Patients retain full autonomy to consult physicians about whether Bryleos products or other marketplace options suit their health needs, aligning with healthcare principles of informed consent and clinical decision-making.
Bryleos’ Mission Focused on Precision Nutrition and Healthy Aging
Wendy Komac, CEO of Bryleos, stated the partnership enables connection with physicians and patients via an innovative healthcare platform emphasizing transparency, accessibility, and quality care. She highlighted Bryleos’ mission to translate rigorous scientific research into meaningful support for healthy aging and cellular wellness, situating the company within the evidence-based health and longevity sector.
Komac referenced precision nutrition and science-backed NAD+ support as key to informed discussions on metabolic health and wellness. This partnership allows Bryleos to educate healthcare consumers and practitioners beyond traditional pharmaceutical or supplement retail channels within a physician-connected marketplace.
Aligning with Healthcare Marketplace Evolution Trends
The Bryleos partnership reflects growing trends in direct-pay and direct-to-consumer healthcare. As patients seek alternatives to insurance-based care, platforms offering transparent pricing, specialist access, and complementary health solutions gain prominence. Integrating Bryleos positions UberDoc at the nexus of specialist medical care and preventive metabolic health support.
This approach responds to demand for healthcare addressing root causes of aging and disease rather than symptoms alone. Emphasizing NAD+ science, cellular resilience, and metabolic health aligns with broader shifts toward prevention, longevity, and functional wellness. For Apptly shareholders, this strategy builds platform value through ecosystem expansion and diversified revenue streams.
Commitment to Regulatory Compliance and Endorsement Transparency
Apptly’s disclosure of its commercial relationship with Bryleos complies with advertising and endorsement regulations, including FTC guidelines and similar frameworks in Canada and elsewhere. These rules require clear disclosure of material connections between endorsers and sellers, particularly in health and wellness sectors.
By committing to transparency, Apptly manages regulatory risks and fosters stakeholder confidence in the marketplace’s credibility. This approach enhances platform integrity while protecting Apptly and partners from enforcement actions or reputational harm due to undisclosed endorsements.
